OTC
SVA

Opera Trading Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

Opera Trading Capital’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-36,146
Closed -$230K – 165
2016
Q1 		$230K Buy
+36,146
New +$217K 0.06% 91

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Opera Trading Capital's SVA Position: Q2 2016 in Review

Opera Trading Capital sold out of Sinovac Biotech, Ltd (SVA) in Q2 2016, closing a stake of 36,146 shares — an estimated $230K sold.

Opera Trading Capital first reported a position in SVA in Q1 2016 and held it in 1 quarter. The position peaked at $230K in Q1 2016. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2016.

  • Opera Trading Capital reported no remaining Sinovac Biotech, Ltd position as of Q2 2016 after selling out during the quarter.
  • Opera Trading Capital sold 36,146 Sinovac Biotech, Ltd shares in Q2 2016, an estimated $230K.
  • Opera Trading Capital first reported a position in Sinovac Biotech, Ltd in Q1 2016 and held it in 1 quarter.
  • Opera Trading Capital's Sinovac Biotech, Ltd position peaked at $230K in Q1 2016.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2016.

Based on Opera Trading Capital's 13F filing for Q2 2016, filed 11 Aug 2016.